Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05807321 · ClinicalTrials.gov registry record · NA
Fecobionics in Biofeedback Therapy in Dyssynergia Patients
A NA study of Constipation and Dyssynergia, sponsored by The California Medical Innovations Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05807321: Recruiting NA study of Constipation and Dyssynergia, sponsored by The California Medical Innovations Institute.
NCT05807321 is a NA study of Constipation and Dyssynergia that is actively recruiting participants, run by The California Medical Innovations Institute. The registered enrollment target is 24 participants, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05807321, a NA study of Constipation and Dyssynergia, is actively recruiting participants, sponsored by The California Medical Innovations Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of physiological parameters during defecation. The aim of the study is to use Fecobionics to assess anorectal function in dyssynergia patients and monitor and predict the outcome of the biofeedback therapy.
Primary Outcome
The time it takes to defecate Fecobionics
Conditions Studied
Interventions
- DEVICE Fecobionics
Study Locations (2)
California
- California Medical Innovations Institute - San Diego
Georgia
- Digestive Health Center- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What NCT05807321 shows while recruiting
NCT05807321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which Fecobionics is the first listed.
NCT05807321 reports a single indexed study location in California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05807321 about?
NCT05807321 is a clinical study titled "Fecobionics in Biofeedback Therapy in Dyssynergia Patients". Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of ...
What is the current status of trial NCT05807321?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2023-10-03. Estimated completion is 2027-03-31.
What conditions does trial NCT05807321 study?
This clinical trial studies the following conditions: Constipation, Dyssynergia.
What interventions are being tested in trial NCT05807321?
The interventions under investigation include: Fecobionics (DEVICE).
Who is sponsoring clinical trial NCT05807321?
This trial is sponsored by The California Medical Innovations Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05807321 being conducted?
This trial has 2 study locations across California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05807321's enrollment target sits among peer trials
24 44th of 54 higher than 11 of 54 other Constipation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimization of Postoperative Bowel Habits
RECRUITING · NA
-
Management of Dyssynergic Defecation
RECRUITING · NA
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
Understanding Mechanisms of Normal and Disordered Defecation
RECRUITING · NA
-
Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes
RECRUITING · NA
-
Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI